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Abstract
Background: Canagliflozin, an oral agent that inhibits sodium glucose co-transporter 2, improves glycemic control,
body weight, and blood pressure and is generally well tolerated in patients with type 2 diabetes mellitus (T2DM).
This study extends the scope of previous analyses by evaluating outcomes associated with the use of canagliflozin
over a 6-month period in a real-world setting.
Methods: This retrospective cohort study used data obtained from a large health plan database for patients
(≥18 years) with a diagnosis of T2DM who filled at least one canagliflozin prescription between April 1, 2013 and
October 30, 2013 (first 7 months canagliflozin was commercially available in the USA) and were continuously
enrolled in the health plan for 6 months prior to (baseline) and 6 months following the first canagliflozin
prescription claim (follow-up). Changes in glycemic control were evaluated, along with characteristics of enrolled
patients and changes in treatment patterns.
Results: 4017 patients (mean age 56 years, 43 % female) met the study inclusion criteria. Of these, at the time of
first canagliflozin claim, 21 % used canagliflozin concomitantly with three or more other antihyperglycemic agents
(AHAs), 29 % with two other AHAs, 30 % with one other AHA, and 20 % without other AHAs. During follow-up,
patients received 3.4 (average) canagliflozin prescription fills and a mean of 148 total days of supply; median
adherence (interquartile range [IQR]) was 86 % (66–98 %) for patients with ≥2 fills. Among patients with available
glycated hemoglobin (A1C) measurements at baseline and follow-up (n = 826, baseline A1C 8.59 %), mean A1C
reduction was 0.81 % (P < 0.001). Mean A1C reduction during the follow-up period was greatest in patients with the
highest baseline A1C levels. Of the patients who used canagliflozin concomitantly with other AHAs, 20 % were
observed to discontinue one or more other AHAs during follow-up. The most commonly discontinued baseline
AHAs were: glucagon-like peptide-1 receptor agonists (16 %), dipeptidyl peptidase-4 inhibitors (15 %), insulin (13 %),
sulfonylureas (13 %), and metformin (11 %).
Conclusions: This real-world study on canagliflozin use in a range of patients with T2DM demonstrated significant
improvements in mean A1C from baseline following the first canagliflozin prescription. In patients concomitantly
using one or more additional AHAs at baseline, there appears to be a trend toward lower other AHA use after
canagliflozin initiation.
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Background
In 2012, the prevalence of diabetes mellitus in the USA
was 29 million [1]. During that same year, diagnosed
diabetes and its associated complications accounted for an
estimated $176 billion in direct medical costs and $69 bil-
lion in indirect costs due to lost work and wages in the
USA [1]. The management of type 2 diabetes mellitus
(T2DM) involves lowering of blood glucose levels, to-
gether with reducing cardiovascular and microvascular risk
factors, i.e., blood pressure- and lipid-lowering therapy, an-
tiplatelet treatment, smoking cessation, and weight loss de-
pending on the needs, preferences, and tolerances of each
patient [1, 2]. The progressive nature of the disease means
that most patients require increasingly intensive pharma-
cologic interventions. Tight glycemic control, defined as
mean glycated hemoglobin (A1C) <7.0 %, is recommended
by the American Diabetes Association (ADA) ‘Standards
of Medical Care in Diabetes’ to reduce the incidence of
microvascular disease [3]. If implemented early in the
course of the disease soon after diagnosis, this stringent
target of A1C <7.0 % for glycemic control is also associated
with a reduction in macrovascular disease [4–6].
Although the value of an A1C goal of <7.0 % is recog-
nized for most patients and is included in the guidelines,
associations such as the ADA and the Agency for
Healthcare Research and Quality stress the importance
of the individualization of treatment goals and the adop-
tion of a patient-centered approach [2, 3, 7]. According
to the ADA, for some patients, more stringent glycemic
goals (e.g., A1C <6.5 %) should be considered, whereas
for other patients, such as those with a history of severe
hypoglycemic episodes or a limited life expectancy, more
relaxed goals (e.g., A1C <8.0 %) may be more appropri-
ate [3]. With National Health and Nutrition Examination
Surveys data from 2007 to 2010 suggesting that almost
half (47.5 %) of all US patients with T2DM fail to
achieve the target goal of A1C <7.0 % [8], less stringent
targets of <8.0 % are likely to be more achievable [9]. Es-
tablishing a goal of weight reduction, or weight mainten-
ance, is also recommended, since even modest weight
loss (5–10 %) contributes meaningfully to achieving im-
proved glucose control and weight outcomes. Further-
more, the proportion of patients achieving target A1C
<7.0 % or <8.0 %, and blood pressure <140/90 mmHg,
are outcomes that health care professionals report to
payers as evidence of good quality patient care in T2DM
treatment [10, 11]. There is a continuing need for more
effective and well-tolerated treatment options that will
help patients with T2DM achieve and maintain glycemic
control, as well as attain other clinically meaningful ben-
efits such as reductions in weight and blood pressure.
A class of oral antihyperglycemic agents (AHAs) is now
available that has the potential to address these needs.
Sodium glucose co-transporter 2 (SGLT2) inhibitors lower
blood glucose via an insulin-independent mechanism, by
inhibiting the reabsorption of filtered glucose in the prox-
imal renal tubules and thereby increasing the excretion of
glucose in the urine. In addition to SGLT2, canagliflozin
also inhibits SGLT1 in the gut, which results in delayed in-
testinal glucose absorption, and may offer added benefits
for patients by reducing postprandial glucose excursions
[12]. Due to its unique mechanism of action, canagliflozin
has been shown to not only reduce blood glucose in pa-
tients with T2DM, but also to reduce body weight and sys-
tolic blood pressure in clinical studies. Furthermore,
canagliflozin is not associated with an increased risk of
hypoglycemic episodes when used as monotherapy or in
combination with agents other than those typically associ-
ated with a high risk of hypoglycemia (such as sulfonylureas
or insulin).
In the 2015 update to the position statement of the
ADA regarding the management of T2DM, the use of
agents that inhibit SGLT2 has been included as an option
for dual therapy (in combination with metformin) or
triple therapy (in combination with metformin plus a
sulfonylurea, thiazolidinedione, dipeptidyl peptidase-4
inhibitor [DPP-4i], or insulin) [3]. The Comprehensive
Diabetes Management Algorithm issued jointly by the
American Association of Clinical Endocrinologists
(AACE) and American College of Endocrinology (ACE)
recommends the use of an SGLT2 inhibitor as a compo-
nent of dual or triple therapy in combination with met-
formin or other AHAs as well as a monotherapy [13, 14].
Canagliflozin, which was approved by the US Food and
Drug Administration (FDA) in March 2013, was the first
SGLT2 inhibitor to enter the US market. The safety and
efficacy of canagliflozin has been established in random-
ized controlled trials. However, an important test of the
effectiveness of any new drug is how it performs in the real
world, beyond the confines of randomized controlled
trials, which require strict inclusion and exclusion criteria
[15, 16]. In a previously published retrospective cohort
study, short-term data were reported for the first 3 months
after the first canagliflozin claim [17]. The current study
aims to extend the scope of this analysis by evaluating out-
comes with a longer follow-up period. As in the original
study, the primary objective of the current analysis was to
evaluate changes in glycemic control (i.e., the attainment
of % A1C goals with canagliflozin). Secondary objectives
included assessing characteristics of patients using canagli-
flozin and changes in the treatment patterns among
patients with T2DM following the first prescription claim
for canagliflozin.
Methods
In this retrospective cohort study, data were obtained
from the Optum Research Database, which contains in-
formation on approximately 14 million commercial and
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500,000 Medicare Advantage enrollees annually, from a
geographically diverse population across the USA [17]. Data
were collated for medical claims, pharmacy claims, labora-
tory results, and socioeconomic status over the 6-month
baseline period (from October 1, 2012) and follow-up
period (between April 1, 2013 and April 30, 2014).
Adult patients (≥18 years) who had a diagnosis of
T2DM (International Classification of Diseases, Ninth
Revision, Clinical Modification [ICD-9-CM] diagnosis
codes 250.×0, 250.×2) and had filled at least one canagli-
flozin prescription between April and October 2013 (the
first 7 months that canagliflozin was available on the US
market) were included in the study. The date of a
patient’s first canagliflozin claim was defined as the
index date. Patients included in the analysis were en-
rolled in the health plan for at least 6 months prior to
the index date (baseline period) and the 6 months fol-
lowing the index date (follow-up period).
Patients were assigned to study cohorts based on the
dose of canagliflozin (100 mg or 300 mg) filled on the
index date. Change in A1C was calculated as the differ-
ence between the baseline period A1C value closest to
the first canagliflozin prescription (baseline value) and
the last A1C value in the 6-month follow-up period oc-
curring at least 30 days after the index date (follow-up
value). The percentage of patients achieving A1C goals
(A1C <7.0 % and <8.0 %) were also evaluated.
Concomitant AHA use with canagliflozin (the ‘baseline
regimen’) was defined as having at least two prescriptions
of any AHA medication class, with one fill during baseline
and one fill on/after the date of the first canagliflozin
claim, without a ≥60-day therapy gap. If patients were not
using any AHA concomitantly with canagliflozin, they
were considered as receiving monotherapy (canagliflozin
only). Treatment was considered discontinued if a ≥60-day
therapy gap was observed in the follow-up period. Canagli-
flozin adherence was assessed as the proportion of days
covered (PDC), calculated as the number of days’ supply of
canagliflozin (including baseline fill) divided by the length
of the follow-up period. In this study, PDC was calculated
for all patients and for the subset of patients with two or
more claims for canagliflozin [18].
The distribution of diabetes-specific complications dur-
ing the baseline period in the study cohort was assessed
using the diabetes complication severity index (DCSI). The
DCSI is a validated diabetes-specific severity scale devel-
oped to predict mortality and hospitalizations. It assesses
the severity of diabetes complications (cardiovascular
disease, nephropathy, retinopathy, peripheral vascular dis-
ease, stroke, neuropathy, and metabolic complications
[e.g., ketoacidosis, diabetic hyperosmolar syndrome, and
coma]) based on the ICD-9 codes and the corresponding
laboratory results [19, 20]. The DCSI was validated using
only the diagnosis codes so that it could be used in the
absence of laboratory data [19, 20]. For this reason, this
ICD-9 code-based assessment of DCSI was chosen in our
analysis.
All results are presented as numbers and percentages
(for dichotomous and polychotomous variables) or as
means, standard deviations, and medians (for continuous
variables). PDC was analyzed as the median and inter-
quartile range (IQR). Descriptive comparisons of base-
line and follow-up medication use and A1C results were
assessed using McNemar tests and paired t-tests (signifi-
cance at P < 0.05).
Results
Baseline characteristics
The baseline characteristics of patients included in the
study are presented in Table 1. A total of 4017 patients
met the study inclusion criteria, and 3581 patients had
two or more claims for canagliflozin. The majority of pa-
tients received their first observed prescription for cana-
gliflozin from a primary care provider (52 %) or an
endocrinologist (27 %). The mean age of patients was
56 years, and 43 % were female. The majority were com-
mercially insured (88 %) and were resident in either the
South (61 %) or the Midwest (20 %) of the USA. Sixty-
nine percent of patients were identified as white, 13 % as
African American, and 11 % as Hispanic.
The mean baseline DCSI value in our sample was 0.85.
Of the included patients, 43 % had at least one condition
included in the baseline DCSI; the most common diag-
nosed complications were neuropathy (18 %), cardio-
vascular conditions (17 %), and nephropathy (10 %).
Baseline renal impairment was identified using serum
creatinine (SCr) levels. The SCr and race data necessary to
calculate estimated glomerular filtration rate (eGFR) were
available for 36 % (n = 1459) of the sample population. Of
these patients, 44 % (n = 635) had values <90 ml/min/
1.73 m2 (some degree of renal impairment) and of these,
>80 % were defined as having stage 2 (mild) chronic
kidney disease (eGFR 60–89 ml/min/1.73 m2).
At the time of the first observed canagliflozin claim,
approximately 30 % of patients (n = 1210) used cana-
gliflozin concomitantly with one other AHA, while
50 % (n = 2012) used canagliflozin with two or more
other AHAs (Fig. 1). Forty-three percent of patients
had concomitant treatment with oral AHAs alone,
14 % with injectable AHAs alone (9 % with insulin
alone), and 23 % with oral and injectable AHAs.
Canagliflozin monotherapy was used in 20 % of pa-
tients (n = 795).
Baseline and follow-up A1C measurements
A total of 826 patients had A1C measurements at
baseline and follow-up. During the baseline period, ap-
proximately 13 % of the 826 patients had A1C <7.0 %,
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and nearly 40 % had A1C <8.0 % (Fig. 2); patients
during this period used, on average, 2.3 AHAs (includ-
ing injectables). In these patients, mean A1C at base-
line was 8.59 %, and was 0.81 % lower in the follow-
up period (P < 0.001 for a comparison of baseline and
follow-up measurements), despite observing fewer
claims for other AHAs during the same time period
(6 months following the index date).
For patients with baseline A1C of ≥7.0 % and available
follow-up laboratory data (n = 715), 21 % and 61 %
Table 1 Baseline characteristics of patients with T2DM treated with canagliflozin. A1C, glycated hemoglobin; DCSI, diabetes
complication severity index; OB/GYM, obstetric/gynecology; SD, standard deviation
Total (N = 4017) 100 mg (n = 2625) 300 mg (n = 1392) 100 mg vs 300 mg P value
Age, mean (SD) 55.6 (9.8) 55.8 (9.8) 55.2 (9.7) 0.039
Female gender, n (%) 1727 (43) 1136 (43) 591 (42) 0.618
Geographic region, n (%)
Northeast 313 (8) 225 (9) 88 (6) 0.011
Midwest 823 (20) 585 (22) 238 (17) <0.001
South 2463 (61) 1561 (59) 902 (65) <0.001
West 418 (10) 254 (10) 164 (12) 0.038
Insurance type, n (%)
Commercial 3542 (88) 2315 (88) 1227 (88) 0.967
Medicare Advantage 475 (12) 310 (12) 165 (12) 0.967
Race, n (%)a
White 2758 (69) 1809 (69) 949 (68) 0.631
African American 517 (13) 350 (13) 167 (12) 0.229
Hispanic 438 (11) 272 (10) 166 (12) 0.130
Asian 69 (2) 50 (2) 19 (1) 0.210
Other 64 (2) 37 (1) 27 (2) 0.202
Unknown/missing 171 (4) 107 (4) 64 (5) 0.436
Baseline DCSI (continuous), mean (SD) 0.85 (1.3) 0.86 (1.3) 0.83 (1.3) 0.460
DCSI complications, n (%)
Neuropathy 741 (18) 477 (18) 264 (19) 0.537
Cardiovascular 677 (17) 445 (17) 232 (17) 0.818
Nephropathy 394 (10) 270 (10) 124 (9) 0.162
Retinopathy 363 (9) 251 (10) 112 (8) 0.111
Peripheral vascular disease 252 (6) 168 (6) 84 (6) 0.649
Cerebrovascular 129 (3) 81 (3) 48 (3) 0.535
Metabolic 39 (1) 22 (1) 17 (1) 0.239
No DCSI complications 2306 (57) 1502 (57) 804 (58) 0.742
Baseline concomitant oral anti-hyperglycemic agents count
(excluding canagliflozin), mean (SD)
2.26 (1.1) 2.28 (1.1) 2.22 (1.1) 0.100
Prescribing provider type, n (%)
Primary care 2100 (52) 1352 (52) 748 (54) 0.178
Endocrinology 1103 (27) 742 (28) 361 (26) 0.115
Not specified 596 (15) 407 (16) 189 (14) 0.102
Other specialty 216 (5) 123 (5) 93 (7) 0.008
OB/GYN 2 (1) 1 (0) 1 (1) 0.648
Baseline A1C results available, n 1295 857 438
Baseline A1C, mean (SD) 8.68 (1.8) 8.72 (1.8) 8.62 (1.7) 0.336
aPercentages may not add up to 100 because of rounding
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achieved glycemic targets of <7.0 % and <8.0 %, respect-
ively, during the 6-month follow-up (Fig. 2).
Among those patients with a baseline A1C of ≥8.0 %
(n = 501), average A1C decreased from 9.54 % at baseline
to 8.24 % in the follow-up period (mean change of
1.30 %), with 14 % and 51 % of patients achieving targets
of <7.0 % and <8.0 %, respectively, at follow-up. For pa-
tients with a baseline A1C of ≥9.0 % (n = 270), average
A1C decreased from 10.51 % at baseline to 8.70 %, with
38 % of patients achieving the goal of <8.0 % in the
follow-up period. The mean A1C reduction during the
follow-up period was greatest in patients with the high-
est baseline A1C levels (Fig. 2).
Canagliflozin treatment on index date and over follow-up
period
The dose of canagliflozin reported on the first claim was
100 mg for 65 % of the population and 300 mg for the
remainder; of the patients initially receiving 100 mg who
had a refill, 30 % up-titrated to 300 mg after an average
of 84 days. Patients received an average of 3.4 canagliflo-
zin prescription fills (mean total days’ supply of 148 days)
with a mean of 74 % (median 83 %) of the days covered.
Median adherence (IQR) to canagliflozin as add-on to 0,
1, 2, or 3 or more AHAs, for patients with 2 or more
canagliflozin fills, was 83 % (59–95 %), 84 % (66–98 %),
90 % (66–98 %), and 92 % (73–99 %). Median adherence
was similar in the subgroup of patients with follow-up
A1C values (data not shown).
Of the patients using canagliflozin in combination with
other AHAs, 20 % appeared to discontinue at least one
of the AHAs from their baseline regimen during the 6-
month follow-up period (Fig. 3). The most common
medications that were discontinued during follow-up
were glucagon-like peptide-1 (GLP-1) receptor agonists
(16 %), DPP-4i (15 %), insulin (13 %), sulfonylureas
(13 %), and metformin (11 %). Discontinuation in the
subgroup of patients with baseline and follow-up A1C
values was generally similar with slightly lower rates of
discontinuation overall, but similar relative differences
between therapies, such as higher rates of discontinu-
ation for bolus vs basal insulin and less metformin dis-
continuation compared with DPP4is and sulfonylureas; a
noteworthy difference was lower discontinuation of pre-
mixed insulin in the subgroup vs the overall population
(4 % vs 14 %; Additional file 1: Figure S1). Change in
A1C was not statistically significantly different among
patients receiving canagliflozin as add-on to 0, 1, 2, or 3
or more AHAs (mean A1C change: 0.86 %, 0.72 %,
0.85 %, and 0.85 %, respectively; P = 0.675)
Discussion
This paper describes the sociodemographic and clinical
characteristics of patients who initiated canagliflozin
during the first 7 months that the drug was available on
the US market. A1C values and patterns of AHA use be-
fore and after the first prescription fill of canagliflozin
show how patients from diverse ethnic and racial back-
grounds, age groups, and regions benefited from better
glycemic control despite a pattern of discontinuation
with other AHAs occurring over the same time period
(6 months). This analysis extends our experience with
canagliflozin compared with a previously published re-
port of 3 months' follow-up [17].
The impact of improved glycemic control on health care
utilization in T2DM is well recognized. Previous analyses
using patient medical claims have reported a 20–24 %
decrease in total diabetes costs when patients were able to
maintain good glycemic control (A1C ≤7.0 %) [21, 22].
This study indicates that treatment of T2DM with
canagliflozin in a real-world population is associated with
substantial reductions in A1C and an increase in the pro-
portion of patients attaining A1C targets. Our findings on
glycemic control are consistent, directionally, with the
results of clinical trials, where canagliflozin treatment has
been shown to be associated with significant decreases in
A1C from baseline values both as monotherapy (−0.77 %
and −1.03 % at 26 weeks with canagliflozin 100 and
300 mg, respectively; −0.73 % and −0.88 % at 52 weeks
with canagliflozin 100 and 300 mg, respectively) and as
add-on therapy to other AHAs (−0.65 % and −0.74 % at
Fig. 1 Concomitant AHA use at the time of the first canagliflozin
claim (N = 4017). Concomitant AHA use was defined based on
treatments the patient had available at the time of the first
canagliflozin claim (there must have been ≥1 claim for the
medication prior to the index date, ≥1 claim for the medication on
or after the index date, and no gap of ≥60 days in the medication
at the time of the first canagliflozin claim). AHA,
antihyperglycemic agent
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104 weeks on metformin with canagliflozin 100 and
300 mg, respectively) [23–26]. At baseline, before the first
prescription-filled claim for canagliflozin, approximately
60 % of patients (with follow-up data) had A1C levels
≥8.0 % indicating poor glycemic control and inadequate
management of their T2DM, despite being treated often
with multiple AHAs (including insulin). During the 6-
month follow-up period, after the first canagliflozin fill
(with or without subsequent fills), a downward trend in
the use of AHAs (other than canagliflozin) was observed,
with the data suggesting that 20 % of the patients no
longer received a filled claim for at least one of the AHAs
from their baseline regimen. Alongside the overall reduc-
tion in AHA claims, significant reductions in A1C levels
were also observed during the follow-up period, with the
greatest A1C reduction in patients with the highest base-
line A1C levels. A greater proportion of patients had A1C
levels <7.0 % during the follow-up period than at baseline,
the period prior to the first canagliflozin claim.
When comparing A1C change in patients who were
more vs less compliant to canagliflozin (PDC ≥ 0.80 vs <
0.80) we did observe a correlation, with a greater mean
change occurring in the more adherent group (0.84 % vs
0.77 %, respectively). However, this correlation was not
statistically significant (P = 0.538).
In summary, the results of this study indicate that
treatment with canagliflozin is associated with improved





Fig. 2 Distribution of baseline and follow-up A1C levels. a. All subjects. b. Baseline A1C ≥7.0 %. c. Baseline A1C ≥8.0 %. d. Baseline A1C ≥9.0 %.
A1C, glycated hemoglobin
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after 6 months. In fact, the results suggest a trend to-
ward lower AHA use for metformin, sulfonylureas, insu-
lin, DPP-4i, GLP-1 agonists, and thiazolidinediones,
ranging from −11 % to −16 %.
Compared with patients in a clinical trial setting, pop-
ulations in real-world settings are generally more diverse
and expected to be less adherent to their treatment regi-
men (e.g., 57 % adherence in the real world and 85 % ad-
herence in clinical trials of statin therapy) [27]. However,
we found that in this real-world study, median treatment
adherence was 83 % in all patients and 86 % in patients
with two or more canagliflozin fills, which is the thresh-
old of high adherence developed by the Pharmacy Qual-
ity Alliance and used by Centers for Medicare and
Medicaid Services to evaluate Medicare plans [28, 29].
The adherence of patients with T2DM to their AHA
regimen is increasingly important and has recently been
adopted as a quantifiable measure associated with the
attainment of A1C goals that has direct consequences
for reimbursement [30, 31]. Furthermore, improved
medication adherence in patients with T2DM has been
shown to be associated with 13 % lower odds of costly
hospitalizations and emergency department visits [32].
The results of the current study indicate that canagliflo-
zin adherence in a real-world setting is within the high
level of adherence values in the Medicare star rating
system. A number of other factors have been identified
that have a negative impact on the treatment adherence
of patients with diabetes, and there have been a number
of systematic reviews of studies investigating interven-
tions with the aim of improving adherence [31, 33]. In
particular, weight gain in patients with T2DM has been
identified as a factor leading to patient frustration that
has a negative impact on compliance with medication
regimens [34]. Conversely, weight loss among patients
with T2DM has been associated with significantly better
adherence to medication, suggesting that therapies asso-
ciated with weight loss may actually improve adherence
[35].
Therapies such as canagliflozin that offer clinical bene-
fits (i.e., reduction of body weight and lowering of blood
pressure) in addition to good glycemic control may help
to increase motivation and self-esteem in patients with
T2DM, leading to greater motivation to conform to
healthy behaviors including medication-taking [36]. Such
benefits can improve the overall effectiveness of therapy
by creating a positive cycle of well-being that motivates
patients to implement and sustain the necessary lifestyle
changes that are an important feature of diabetes self-
management.
As with all observational studies leveraging adminis-
trative claims data, there are limitations to consider
when interpreting study results. One of the potential
limitations of administrative claims is the accuracy of
the medical and pharmaceutical history captured in the
claims data. These data might be subject to possible cod-
ing errors, where some diagnoses may be missed or used
incorrectly.
As this was an observational study, patients were not
proactively followed up, but rather we were limited to
the use of the baseline and follow-up A1C data that were
available in the database at the time of sampling. Since
baseline and follow-up A1C values were only available
for 826 patients, the results may not be representative of
the entire study population. It is unknown why follow-
up data were not available for a subset of patients, but
Fig. 3 AHAs included in baseline regimen and with continued use in follow-up (N = 4017). Medications included in the AHA regimen at the time
of the canagliflozin fill were further assessed in the follow-up period for evidence of discontinuation. Treatment was considered discontinued if a
≥60 day gap in therapy was observed. DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1
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this is probably the result of many factors including dif-
ferences between physicians in the timing of taking
follow-up A1C measurements and point-of-care A1C
measurements that would not be captured in claims or
laboratory databases. It is plausible that patients with
follow-up A1C values were receiving a better standard of
care or were of a higher socioeconomic status and thus
able to afford more frequent health care visits. It is also
possible that patients without follow-up A1C values
were generally ‘healthier’ patients who tended to interact
with health care professionals less frequently.
Baseline characteristics of the subgroup of patients
with baseline and follow-up A1C values were generally
similar to the overall cohort with a few exceptions (Add-
itional file 2: Table S1): in the overall cohort, female pa-
tients were more represented (43 % vs 40 %), as were
patients from the Midwest region (20 % vs 11 %),
whereas patients with commercial insurance were less
represented (88 % vs 91 %).
A follow-up period of longer than 6 months would be
informative as a greater proportion of the patient popu-
lation may have follow-up laboratory data available. This
will form the basis of a future investigation.
Additionally, as a real-world study aimed at under-
standing pre- vs post-changes in various outcome mea-
sures in patients receiving canagliflozin, no control
group was employed. With an increase in sample size
and longer follow-up, future studies should aim to gen-
erate comparative effectiveness evidence.
Since only pharmacy and laboratory follow-up data
were available for analysis, the assessment of adverse
events or DSCI at follow-up were beyond the scope of
this study. However, the high rate of adherence to
canagliflozin during the follow-up period provides some
indication of the tolerability of the index therapy. To the
best of our knowledge, to date, only one study has evalu-
ated adverse events in patients taking canagliflozin in
the real world. In a study based upon electronic medical
records, Nardolillo et al. found that canagliflozin was
generally well tolerated when added to other AHAs in a
real-world setting [37]. Future studies should consider a
detailed examination of the adverse event profiles of
patients using canagliflozin in the real-world.
It would have been informative to observe changes in
insulin dose or regimen from baseline to follow-up.
However, as insulin dose is unique to each patient,
capturing changes in insulin dose from administrative
claims data was beyond the scope of this study. It would
also be informative to understand the timing of discon-
tinuation of AHAs relative to changes in A1C, and vice
versa. Given the relatively short 6-month follow-up
period, this analysis was not performed. However, such
an analysis will be considered when longer-term data
become available.
Adherence data need to be regarded with some cau-
tion. The often suboptimal medication adherence of pa-
tients in the real world should be taken into account.
Patients may not have taken their medications as speci-
fied on their prescription claim or may have received oc-
casional samples of medications without the presence of
a claim. However, PDC data do indicate that patients
were making the effort to refill their medications. Future
studies of the use of SGLT2 inhibitors in the real world
should provide a specific focus on treatment adherence
in addition to outcomes such as glycemic control and
weight loss.
In the 6-month follow-up period, a median adherence
of 86 % for patients with two or more canagliflozin fills
was observed. Future research will aim to evaluate treat-
ment patterns using longer-term data when they become
available. Patient data used for this study were from a
commercial and Medicare Advantage managed-care
population with 12 months of continuous health plan
enrollment. Therefore, the findings of the analysis herein
are applicable to patients with T2DM on similar therap-
ies in managed-care settings. Since the plans used for
analysis include a wide geographic distribution across
the USA, they provide the capability for generalization
to managed-care populations on a national level.
Conclusions
In this real-world study of canagliflozin use during the
period immediately following FDA approval, canagliflo-
zin was prescribed to patients with a range of baseline
A1C values whose glycemic levels were often uncon-
trolled (87 % with A1C ≥7.0 %) despite being managed
with multiple AHAs, including insulin therapy. Signifi-
cant improvements in A1C were observed in the
6 months (average time to follow-up from index date:
112 days) following the first canagliflozin prescription,
with results consistent with those observed in the cana-
gliflozin randomized clinical trials. The results of this
study show that, following initiation of treatment with
canagliflozin as monotherapy, or as add-on therapy to
multiple AHAs (including oral and injectable agents), a
substantial proportion of patients in a real-world setting
were able to attain their A1C goals, with a trend to
lower other AHA use, indicating canagliflozin could po-
tentially lead to cost offsets in the treatment of T2DM.
Additional files
Additional file 1: Figure S1. AHAs included in baseline regimen and
with continued use in follow-up in patients with baseline and follow-up
A1C measurements (N = 826). Medications included in the AHA regimen
at the time of the canagliflozin fill were further assessed in the follow-up
period for evidence of discontinuation. Treatment was considered discon-
tinued if a ≥60 day gap in therapy was observed. DPP-4i, dipeptidyl
peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1. (PDF 82 kb)
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Additional file 2: Table S1. Baseline characteristics of patients with
T2DM with baseline and follow-up A1C measurements treated with cana-
gliflozin. A1C, glycated hemoglobin; DCSI, diabetes complication severity
index; OB/GYM, obstetric/gynecology; SD, standard deviation. (DOC 36
kb)
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